9/26/2011

People age 50 and older should be allowed to receive Prevenar 13, a pneumococcal vaccine by Pfizer, said the European Medicines Agency's Committee for Medicinal Products for Human Use. The vaccine is indicated for younger children in the EU and the U.S., where it is marketed as Prevnar 13. The FDA previously asked for more time to evaluate the wider use.

Full Story:
Reuters

Related Summaries